Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

HB 2797Session 2025-2026

An Act providing for 340B drug reimbursement, for reimbursement claims methodology, for safety net reimbursement protection, for safety net prescription drug distribution and access protections and for enforcement; and imposing penalties.

Printer's No. PN3953

See other bills
under the
same topic PRINTER'S NO. 3953 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE BILL No.2797 Session of 2026 INTRODUCED BY ORTITAY AND KHAN, SEPTEMBER 24, 2026 REFERRED TO COMMITTEE ON HUMAN SERVICES, SEPTEMBER 29, 2026 AN ACTProviding for 340B drug reimbursement, for reimbursement claims methodology, for safety net reimbursement protection, for safety net prescription drug distribution and access protections and for enforcement; and imposing penalties.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Short title.This act shall be known and may be cited as the Safety Net Nondiscrimination Act.Section 2. Definitions.The following words and phrases when used in this act shall have the meanings given to them in this section unless the context clearly indicates otherwise:"340B drug." A drug that is a covered outpatient drug within the meaning of 42 U.S.C. § 256b (relating to limitation on prices of drugs purchased by covered entities), that a manufacturer is required to offer to a covered entity at a reduced price under 42 U.S.C. § 256b and that is purchased by a covered entity. For the purposes of this definition, a drug 12345678910111213141516171819 shall be deemed to be purchased by a covered entity if the drug would have been purchased but for a violation of section 6."Contract pharmacy." A pharmacy under contract with a covered entity to provide services to and on behalf of the covered entity with respect to 340B drugs purchased by the covered entity."Covered entity." An entity specified in 42 U.S.C. § 256b(a)(4) that participates or is authorized to participate in the program under 42 U.S.C. § 256b."Covered insurer." As follows:(1) A Medicaid managed care organization.(2) An entity that reimburses a covered entity or contract pharmacy for prescription drugs or dispensing services on behalf of a patient, including an entity licensed by the Insurance Department with accident and health authority to issue a health insurance policy governed under any of the following:(i) The act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, including section 630 and Article XXIV of that act.(ii) The act of December 29, 1972 (P.L.1701, No.364), known as the Health Maintenance Organization Act.(iii) 40 Pa.C.S. Ch. 61 (relating to hospital plan corporations) or 63 (relating to professional health services plan corporations).(3) The term does not include any of the following:(i) The medical assistance fee-for-service program under Article IV of the act of June 13, 1967 (P.L.31, No.21), known as the Human Services Code.20260HB2797PN3953 - 2 - 123456789101112131415161718192021222324252627282930 (ii) An individual paying for a drug on the individual's own behalf or on behalf of another individual.(iii) The Pennsylvania Employees Benefit Trust Fund or a successor organization that only provides prescription drug benefits for employees of the Commonwealth and their covered dependents.(iv) The Special Pharmaceutical Benefits Program operated by the department."Department." The Department of Human Services of the Commonwealth."Drug." As defined in section 2 of the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act."Mail delivery." Dispensing or delivering a drug by mail, courier or shipping service."Manufacturer." As defined in section 2 of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act. The term includes a manufacturer of a biological product."Medicaid managed care organization." As defined in 42 U.S.C. § 1396b(m)(1)(A) (relating to payment to States). The term includes a person or entity that administers or manages prescription drug benefits on behalf of the Medicaid managed care organization or the department with respect to the Medicaid managed care organization."Package." As defined in 21 U.S.C. § 360eee(11) (relating to definitions)."Pharmacy." As defined in section 2 of the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act."Pharmacy benefits management." Any of the following:20260HB2797PN3953 - 3 - 123456789101112131415161718192021222324252627282930 (1) Administration or management of pharmacy benefits provided by a covered insurer for the benefit of individuals.(2) Administration of pharmacy benefits, including any of the following:(i) Claims processing.(ii) Retail pharmacy network management.(iii) Paying claims to pharmacies for prescription drugs dispensed to covered individuals by a retail, specialty or mail-order pharmacy.(iv) Developing and managing a clinical formulary, utilization management and quality assurance program.(v) Rebate contracting and administration.(vi) Managing a patient compliance, therapeutic intervention and generic substitution program.(vii) Operating a disease management program.(viii) Setting pharmacy reimbursement pricing and methodologies, including maximum allowable cost, and determining single or multiple source drugs."Pharmacy benefits manager." A person, business or other entity that performs pharmacy benefits management for covered insurers."Sexually transmitted disease clinic." A covered entity or an entity eligible to become a covered entity that, on or after the effective date of this definition, receives support from the department under a participating provider agreement funded under 42 U.S.C. § 247c (relating to sexually transmitted diseases; prevention and control projects and programs).Section 3. Minimum reimbursement for 340B drugs.(a) Minimum reimbursement.--A pharmacy benefits manager, covered insurer or agent acting on behalf of a pharmacy benefits 20260HB2797PN3953 - 4 - 123456789101112131415161718192021222324252627282930 manager or covered insurer that reimburses a covered entity or contract pharmacy for a drug under a contract may not reimburse the covered entity or contract pharmacy in an amount less than:(1) The national average drug acquisition cost determined based on surveys conducted under 42 U.S.C. § 1396r-8(f) (relating to payment for covered outpatient drugs) for a 340B drug for which a national average drug acquisition cost is available.(2) The wholesale acquisition cost as defined in 42 U.S.C. § 1395w-3a(c)(6)(B) (relating to use of average sales price payment methodology) for a 340B drug for which a national average drug acquisition cost is not available.(b) Waiver.--A covered entity may, in the sole discretion of the covered entity, voluntarily waive the protections under subsection (a). A person may not obtain a waiver under this subsection through direct or indirect coercion.Section 4. Reimbursement claims methodology.The department, a covered insurer, a pharmacy benefits manager or another entity that administers or manages prescription drug benefits on behalf of the department or a Medicaid managed care organization shall, with respect to payment for drugs under Medicaid, rely exclusively on a claims-level methodology that uses a nationally recognized billing modifier to identify drugs purchased under 42 U.S.C. § 256b (relating to limitation on prices of drugs purchased by covered entities) to ensure that utilization data for the drugs are excluded from the information reported under 42 U.S.C. § 1396b(m)(2)(A)(xiii) (relating to payment to States) and from Medicaid drug rebate requests.Section 5. Safety net reimbursement protection.20260HB2797PN3953 - 5 - 123456789101112131415161718192021222324252627282930 (a) Prohibited conduct.--A Medicaid managed care organization may not:(1) Take any of the following actions with respect to a 340B drug:(i) Prevent a covered entity or contract pharmacy from administering or dispensing a 340B drug by any lawful means, including mail delivery.(ii) Prevent a covered entity or contract pharmacy from submitting a claim for reimbursement for a 340B drug.(iii) Decline to cover a claim for reimbursement for a 340B drug that was administered or dispensed.(2) Impose a limitation on the distance between a covered entity and a contract pharmacy or between a covered entity or contract pharmacy and a patient.(3) Except as necessary to comply with Federal law, request, require or compel the transmission of ingredient cost, pricing data or other data pertaining to the program under 42 U.S.C. § 256b (relating to limitation on prices of drugs purchased by covered entities).(b) Abrogation.--A rule, regulation or statement of policy that is inconsistent with subsection (a) is abrogated to the extent of the inconsistency.(c) Outpatient prescription drug coverage.--The department shall maintain coverage for all outpatient prescription drugs through Medicaid managed care organizations for as long as any medical assistance service described in 42 U.S.C. § 1396d(a) (relating to definitions) is delivered by a Medicaid managed care organization.(d) Federal grant funding.--The department shall take the 20260HB2797PN3953 - 6 - 123456789101112131415161718192021222324252627282930 following actions:(1) No later than 90 days after the effective date of this paragraph, provide each sexually transmitted disease clinic a grant of at least $500 from the department's Federal funding under 42 U.S.C. § 247c (relating to sexually transmitted diseases; prevention and control projects and programs) to perform sexually transmitted disease testing and treatment.(2) Provide in each new award or renewal to a sexually transmitted disease clinic a grant of at least $500 from the department's Federal funding under 42 U.S.C. § 247c to perform sexually transmitted disease testing and treatment.Section 6. Safety net prescription drug distribution and access protections.(a) Distribution and access.--A manufacturer, an agent or affiliate of a manufacturer or a third-party logistics provider may not, directly or indirectly, take any of the following actions unless the acquisition or receipt of the 340B drug is prohibited by Federal law:(1) Deny, restrict, prohibit, delay or otherwise interfere with the acquisition of a 340B drug by, or delivery of a 340B drug to, a covered entity or contract pharmacy.(2) Place a condition on the acquisition or receipt of a 340B drug by a covered entity or contract pharmacy.(b) Claims and utilization data.--A manufacturer or an agent or affiliate of a manufacturer may not, directly or indirectly, require a covered entity to submit claims or utilization data as a condition for allowing the acquisition of a 340B drug by, or delivery of a 340B drug to, the covered entity unless submission of the claims or utilization data is required by Federal law.20260HB2797PN3953 - 7 - 123456789101112131415161718192021222324252627282930 Section 7. Enforcement, penalties and remedies.(a) Insurance Department.--The Insurance Department shall investigate complaints alleging violations of sections 3 and 5(a) and enforce those provisions. In administering this subsection, the Insurance Department may:(1) Examine or audit the books and records of a pharmacy benefits manager, covered insurer or related party to determine compliance with this act.(2) Issue subpoenas as necessary to carry out enforcement and oversight under this act.(b) Section 6 enforcement.--(1) A violation of section 6 shall constitute an unlawful practice within the meaning of the act of December 17, 1968 (P.L.1224, No.387), known as the Unfair Trade Practices and Consumer Protection Law. The Office of Attorney General shall have jurisdiction, consistent with the Unfair Trade Practices and Consumer Protection Law, to enforce section 6 and may promulgate regulations to implement section 6.(2) The department may promulgate regulations consistent with section 6. The department may investigate a complaint alleging a violation of section 6 by an individual or entity licensed by or registered with the department, impose discipline on the individual or entity, suspend or revoke the license or registration of the individual or entity and issue subpoenas as necessary to administer enforcement and oversight under this act.(c) Civil penalties.--(1) Upon written notice, the Insurance Department shall impose a civil penalty on a pharmacy benefits manager or 20260HB2797PN3953 - 8 - 123456789101112131415161718192021222324252627282930 covered insurer as follows:(i) For a violation of section 3 or section 5(a), other than section 5(a)(2), $1,000 for each wrongfully denied claim or improperly paid claim.(ii) For a violation of section 5(a)(2), $1,000 per day for each contract pharmacy excluded as a result of a limitation under section 5(a)(2).(2) Upon written notice, the Office of Attorney General shall impose a civil penalty of $50,000 for each violation of section 6 by a manufacturer or an agent or affiliate of a manufacturer. The aggregate amount of civil penalties imposed under this paragraph may not exceed $10,000,000 per year. Each package of a 340B drug that is subject to prohibited conduct under section 6 shall constitute a separate violation.(d) Suspension.--(1) If a violation of section 3 or 5(a) is not corrected within 30 days after the date on which written notice is sent under subsection (c), the Insurance Department shall suspend the right of the pharmacy benefits manager or covered insurer, including a Medicaid managed care organization, to conduct business in this Commonwealth.(2) If a violation of section 6 is not corrected within 30 days after the date on which written notice is sent under subsection (c), the Office of Attorney General shall suspend the right of the manufacturer or agent or affiliate of the manufacturer to conduct business in this Commonwealth.(e) Contracts.--A term of a contract entered into on or after the effective date of this subsection that violates section 3 or 5(a) is void.20260HB2797PN3953 - 9 - 123456789101112131415161718192021222324252627282930 (f) Injunctive relief.--A covered entity or contract pharmacy may immediately commence an action for injunctive relief in Commonwealth Court to enforce this act.Section 8. Construction.(a) Federal law.--This act shall be construed and applied so that it is not less restrictive than applicable Federal law with respect to a person or entity regulated under this act. Nothing in this act shall be construed or applied in a manner that conflicts with applicable Federal law or related regulations, including 42 U.S.C. Ch. 7, Subch. XI, Pt. E (relating to price negotiation program to lower prices for certain high-priced single source drugs).(b) Other laws of Commonwealth.--Nothing in this act shall be construed or applied in a manner that conflicts with another law of this Commonwealth that is compatible with applicable Federal law. If this act and the act of November 21, 2016 (P.L.1318, No.169), known as the Pharmacy Benefit Reform Act, both apply, this act shall be construed to provide greater protection for covered entities and contract pharmacies.(c) Limited distribution.--Limited distribution of a drug required under 21 U.S.C. § 355-1 (relating to risk evaluation and mitigation strategies) shall not constitute a violation of this act.Section 9. Effective date.This act shall take effect immediately.20260HB2797PN3953 - 10 - 12345678910111213141516171819202122232425

Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.